University of Alabama at Birmingham researchers have identified a therapeutic target to prevent or delay heart failure from pressure overload of the heart, and a potential biomarker for the same.

A new study published in JAMA Cardiology by UAB researchers shows that a key protein released from the heart is almost 35-percent lower in African-Americans than in Caucasians, and predicts the risk of death, particularly cardiovascular mortality similarly in both races.

This more comprehensive approach may be needed to find ways to delay the progressive heart failure.

A UAB spinoff has received a stage two grant to test a potential solution for malfunctioning vascular access.

The 11 postdocs selected to receive Outstanding Postdoctoral Awards represent nine departments, divisions and schools across UAB.

UAB Medicine has a long history of caring for patients with adult congenital heart disease, and the Alabama Adult Congenital Heart Program is the only one in Alabama and one of a handful in the country that provide continuing care for patients as they move into adulthood.

A program that supports historically disadvantaged health professionals chooses two researchers in the UAB Department of Medicine as finalists.

A fatty acid-derived bioactive molecule called lipoxin improved heart function after a heart attack, as the lipoxin prompted early activation of the resolving phase of the immune response.

Knowledge from this study and others may help physicians boost healing and prevent heart failure in patients after a heart attack.

These leaders represent the next generation of cardiologists who are working to educate their colleagues, conduct research on new and novel strategies to advance cardiovascular care, and innovate the unique aspects of the cardiology specialty.